All In Biotech

Drug Trial Radar · NCT07266428

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Ottimo Pharma LimitedIndustry
Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues. * Have radiographic scans of their tumor at baseline and during the study at regular intervals. * Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.

Conditions

  • Advanced Solid Tumors

Interventions

  • OTP-01Drug

    Intravenous (IV) Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 and Phase 2A: Frequency and Severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: C1D1 through EoT (up to 36 months)
  2. Phase 2A - Progression Free Survival (PFS)Time frame: C1D1 through EoT (up to 36 months)
  3. Phase 2A - Disease Control Rate (DCR)Time frame: C1D1 through EoT (up to 36 months)
  4. Phase 2A - Duration of Response (DOR)Time frame: C1D1 through EoT (up to 36 months)
  5. Phase 2A - Objective Response Rate (ORR)Time frame: C1D1 through EoT (up to 36 months)

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • South Texas Accelerated Research Therapeutics (START) Midwest

    Grand Rapids, Michigan · Recruiting

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • Cancer Research SA

    Adelaide, Australia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Australia · Recruiting

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia

    Ijuí, Brazil · Recruiting

  • Centro Gaucho Integrado

    Porto Alegre, Brazil · Recruiting

  • Instituto do Cancer do Estado de São Paulo (ICESP)

    São Paulo, Brazil · Recruiting

  • Oncostar

    São Paulo, Brazil · Recruiting

  • START Dublin Early Phase Clinical Trials Unit

    Dublin, Ireland · Recruiting

  • Auckland City Hospital

    Auckland, New Zealand · Recruiting

  • Hospital de Santa-Maria-Centro Hospitalar Lisboa Norte (CHLN)

    Lisbon, Portugal · Recruiting

  • NEXT Oncology Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • NEXT Oncology Madrid

    Madrid, Spain · Recruiting

  • START - Rioja

    Rioja, Spain · Recruiting

  • Ankara Bilkent City Hospital

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Oncology Training and Research Hospital

    Ankara, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.